Tumor  ||| S:0 E:6 ||| NN
necrosis  ||| S:6 E:15 ||| NN
factor  ||| S:15 E:22 ||| NN
and  ||| S:22 E:26 ||| CC
anti-tumor  ||| S:26 E:37 ||| JJ
necrosis  ||| S:37 E:46 ||| FW
factor  ||| S:46 E:53 ||| FW
therapies  ||| S:53 E:63 ||| FW
Tumor  ||| S:63 E:69 ||| FW
necrosis  ||| S:69 E:78 ||| FW
factor  ||| S:78 E:85 ||| FW
( ||| S:85 E:86 ||| -LRB-
TNF ||| S:86 E:89 ||| NNP
)  ||| S:89 E:91 ||| -RRB-
plays  ||| S:91 E:97 ||| VBZ
a  ||| S:97 E:99 ||| DT
crucial  ||| S:99 E:107 ||| JJ
role  ||| S:107 E:112 ||| NN
in  ||| S:112 E:115 ||| IN
the  ||| S:115 E:119 ||| DT
pathogenesis  ||| S:119 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
immune-mediated  ||| S:135 E:151 ||| JJ
inflammatory  ||| S:151 E:164 ||| JJ
diseases  ||| S:164 E:173 ||| NNS
( ||| S:173 E:174 ||| -LRB-
IMID ||| S:174 E:178 ||| NNP
) ||| S:178 E:179 ||| -RRB-
.  ||| S:179 E:181 ||| .
As  ||| S:181 E:184 ||| IN
a  ||| S:184 E:186 ||| DT
result ||| S:186 E:192 ||| NN
,  ||| S:192 E:194 ||| ,
the  ||| S:194 E:198 ||| DT
inhibition  ||| S:198 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
TNF  ||| S:212 E:216 ||| NNP
is  ||| S:216 E:219 ||| VBZ
an  ||| S:219 E:222 ||| DT
important  ||| S:222 E:232 ||| JJ
therapeutic  ||| S:232 E:244 ||| JJ
avenue  ||| S:244 E:251 ||| NN
in  ||| S:251 E:254 ||| IN
the  ||| S:254 E:258 ||| DT
treatment  ||| S:258 E:268 ||| NN
of  ||| S:268 E:271 ||| IN
these  ||| S:271 E:277 ||| DT
pathophysiologically  ||| S:277 E:298 ||| JJ
diverse  ||| S:298 E:306 ||| JJ
disease  ||| S:306 E:314 ||| NN
states ||| S:314 E:320 ||| NNS
.  ||| S:320 E:322 ||| .
This  ||| S:322 E:327 ||| DT
section  ||| S:327 E:335 ||| NN
discusses  ||| S:335 E:345 ||| VBD
TNF ||| S:345 E:348 ||| NNP
,  ||| S:348 E:350 ||| ,
its  ||| S:350 E:354 ||| PRP$
receptors ||| S:354 E:363 ||| NNS
,  ||| S:363 E:365 ||| ,
and  ||| S:365 E:369 ||| CC
its  ||| S:369 E:373 ||| PRP$
role  ||| S:373 E:378 ||| NN
in  ||| S:378 E:381 ||| IN
immunoregulation  ||| S:381 E:398 ||| NN
and  ||| S:398 E:402 ||| CC
inflammation ||| S:402 E:414 ||| NN
,  ||| S:414 E:416 ||| ,
as  ||| S:416 E:419 ||| RB
well  ||| S:419 E:424 ||| RB
as  ||| S:424 E:427 ||| IN
the  ||| S:427 E:431 ||| DT
currently  ||| S:431 E:441 ||| RB
available  ||| S:441 E:451 ||| JJ
anti-TNF-based  ||| S:451 E:466 ||| JJ
therapies ||| S:466 E:475 ||| NNS
.  ||| S:475 E:477 ||| .
